NCT06737354View on ClinicalTrials.gov

Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 22, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2031

Conditions
nAMD
Interventions
GENETIC

IVB103 Injection（Low dose）

Single intravitreal injection

GENETIC

IVB103 Injection（Intermediate dose）

Single intravitreal injection

GENETIC

IVB103 Injection（High dose）

Single intravitreal injection

Trial Locations (1)

610000

West China Hospital of Sichuan University, Chengdu

Sponsors
All Listed Sponsors
collaborator

NeoVec Biotherapeutics Inc.

INDUSTRY

lead

InnoVec Biotherapeutics Inc.

INDUSTRY

NCT06737354 - Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD). | Biotech Hunter | Biotech Hunter